Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 5
Submit an article Journal homepage
1,117
Views
5
CrossRef citations to date
0
Altmetric
Surgery

Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study

Charles V. Pollack JrThomas Jefferson University, Philadelphia, PA, USA; Correspondence[email protected]
,
Richard BernsteinNorthwestern University, Chicago, IL, USA;
,
Robert DubielBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA;
,
Paul ReillyBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA;
,
Fredrik GruenenfelderBoehringer Ingelheim Corporation, Ingelheim, Germany;
,
Menno V. HuismanLeiden University Medical Center, Leiden, the Netherlands;
,
Chak-Wah KamTuen Mun Hospital, Tuen Mun, New Territories, Hong Kong, PR China;
,
Eva KleineBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;
,
Jerrold H. LevyDuke University Medical Center, Durham, NC, USA;
,
Frank W. SellkeRhode Island Hospital, Brown Medical School, Providence, RI, USA;
,
Thorsten SteinerKlinik für Neurologie, Klinikum Frankfurt Höchst, Frankfurt and Universitätsklinikum, Heidelberg, Germany;
,
Anastasia UstyugovaBoehringer Ingelheim GmbH, Ingelheim, Germany;
&
Jeffrey I. WeitzMcMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
 show all
Pages 435-442 | Received 05 Aug 2016, Accepted 13 Dec 2016, Published online: 17 Jan 2017

References

  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
  • Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72
  • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
  • Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
  • Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e44S-e88S
  • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27
  • Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-62
  • Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-90
  • Pollack CV, Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;114:198-205
  • Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20
  • Peetermans M, Pollack C, Jr., Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila) 2016;54:644-6
  • Corral M, Ferko N, Hollmann S, et al. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. Clinicoecon Outcomes Res 2015;7:409-21
  • Douketis JD, Healey JS, Brueckmann M, et al. Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. Thromb Res 2016;139:77-81
  • Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126:343-8
  • Dentali F, Marchesi C, Giorgi PM, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429-38
  • Marshall A, Levine M, Howell ML, et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost 2016;14:324-30
  • Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128:2325-32

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.